Company news
Bluenergies Ltd. (TSXV:BLU) news
Bluenergies Ltd. news releases on 6ix. Latest, Aug 20, 2009: BayStreet.ca Research Alert: BELLUS Health Inc.
Press releases — page 4
BayStreet.ca Research Alert: BELLUS Health Inc.
August 20, 2009
BELLUS Health reports results for first half of fiscal 2009
August 11, 2009
VIVIMIND(TM) granted certificate of free sale as food supplement in Italy - Premarket notification filed in the U.S.
July 16, 2009
BELLUS Health Inc. Announces Record Date for $12 Million Rights Offering To Common Shareholders
July 15, 2009
BELLUS Health Inc. Announces $12 Million Rights Offering To Common Shareholders
July 7, 2009
BELLUS Sante annonce que les resultats exploratoires publies dans une revue revisee par des pairs revelent que le tramiprosate ralentit l'atrophie de l'hippocampe cerebral et presentent des preuves preliminaires d'effets benefiques sur la cognition
July 6, 2009
BELLUS Health Announces Exploratory Results in Peer-Reviewed Publication Reveal Tramiprosate Slows Atrophy of Brain Hippocampus with Preliminary Evidence of Beneficial Effect on Cognition
July 6, 2009
FMRC Family Trust completes reorganization of itsholdings of securities of Bellus Health Inc.
June 25, 2009
BELLUS Sante inc. annonce la nomination d'un dirigeant
June 5, 2009
BELLUS Health Inc. Announces Officer
June 5, 2009
Assemblee generale des actionnaires - BELLUS Sante fait le point sur les progres de l'entreprise et de sa situation financiere
June 4, 2009
Annual General Meeting of Shareholders - BELLUS Health provides updates on corporate and financial developments
June 4, 2009
Assemblee annuelle des actionnaires de BELLUS Sante inc. le 4 juin 2009
June 2, 2009
BELLUS Health Inc. Annual General Meeting of Shareholders June 4, 2009
June 2, 2009
BELLUS Health reports results for first quarter of fiscal 2009
May 6, 2009
BELLUS announces Chief Financial Officer to depart effective May 22, 2009
April 24, 2009
BELLUS Health inc. announces completion of first tranche of financing
April 16, 2009
Bellus Health Inc. provides an update on the financing and the restructuring of existing notes
April 8, 2009
BELLUS Health Inc. provides financing update and announces restructuring of existing notes
March 31, 2009
BELLUS Sante Inc. fait une mise au point concernant son financement
March 24, 2009
BELLUS Health provides financing update
March 24, 2009
BELLUS Sante annonce des reductions de personnel afin de reduire ses frais d'exploitation
March 12, 2009
BELLUS Health announces staff reductions to lower operating expenses
March 12, 2009
BELLUS Health reports results for the fourth quarter of 2008
February 26, 2009
BELLUS Health announces formal notice to voluntarily delist from NASDAQ
December 17, 2008
BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
December 5, 2008
BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
November 13, 2008
BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
November 10, 2008
BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
November 6, 2008
BELLUS Health provides update on activities
October 21, 2008
BELLUS Health Receives Nasdaq Deficiency Notice Relating to Market Value
October 15, 2008
VIVIMIND(TM), Canada's scientifically proven natural health product to protect memory function, is available starting today
September 2, 2008
Correction from source - BELLUS Health
August 12, 2008
BELLUS Health moves forward on nutraceutical and pharmaceutical fronts - Reports Results for First Half of 2008
August 5, 2008
BELLUS Health announces closing of Innodia acquisition
July 17, 2008
BELLUS Health signs agreement to acquire Innodia
July 16, 2008
BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
May 15, 2008
BELLUS HEALTH reports results for first quarter of fiscal 2008
May 5, 2008
At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
April 15, 2008
Media advisory - Neurochem's Annual and Special Meeting of Shareholders April 15, 2008
April 11, 2008
Neurochem Annual and Special Meeting of shareholders
April 11, 2008
Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
March 13, 2008
Neurochem announces departure of two members of management team
February 21, 2008
Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
February 20, 2008
/C O R R E C T I O N from source -- Neurochem Inc./
February 13, 2008
Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
February 11, 2008
Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
January 30, 2008
Neurochem to present at JPMorgan Healthcare Conference
January 3, 2008
Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
December 14, 2007
Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
December 6, 2007